View Item 

Show simple item record

Safety, tolerability, and pharmacokinetics of l‐ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia
dc.contributor.authorStravitz, R. Todd
dc.contributor.authorGottfried, Michelle
dc.contributor.authorDurkalski, Valerie
dc.contributor.authorFontana, Robert J.
dc.contributor.authorHanje, A. James
dc.contributor.authorKoch, David
dc.contributor.authorHameed, Bilal
dc.contributor.authorGanger, Daniel
dc.contributor.authorSubramanian, Ram M.
dc.contributor.authorBukofzer, Stan
dc.contributor.authorRavis, William R.
dc.contributor.authorClasen, Kristen
dc.contributor.authorSherker, Averell
dc.contributor.authorLittle, Lanna
dc.contributor.authorLee, William M.
dc.date.accessioned2018-03-07T18:23:27Z
dc.date.available2019-05-13T14:45:23Zen
dc.date.issued2018-03
dc.identifier.citationStravitz, R. Todd; Gottfried, Michelle; Durkalski, Valerie; Fontana, Robert J.; Hanje, A. James; Koch, David; Hameed, Bilal; Ganger, Daniel; Subramanian, Ram M.; Bukofzer, Stan; Ravis, William R.; Clasen, Kristen; Sherker, Averell; Little, Lanna; Lee, William M. (2018). "Safety, tolerability, and pharmacokinetics of l‐ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia." Hepatology 67(3): 1003-1013.
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.urihttps://hdl.handle.net/2027.42/142428
dc.publisherWiley Periodicals, Inc.
dc.titleSafety, tolerability, and pharmacokinetics of l‐ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142428/1/hep29621.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142428/2/hep29621-sup-0001-suppinfo1.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142428/3/hep29621_am.pdf
dc.identifier.doi10.1002/hep.29621
dc.identifier.sourceHepatology
dc.identifier.citedreferenceConn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, et al. Comparison of lactulose and neomycin in the treatment of chronic portal‐systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: 573 ‐ 583.
dc.identifier.citedreferenceReuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz RT, et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann Intern Med 2016; 164: 724 ‐ 732.
dc.identifier.citedreferenceKumar R, Shalimar, Sharma H, Prakash S, Panda SK, Khanal S, et al. Persistent hyperammonemia is associated with complications and poor outcomes in patients with acute liver failure. Clin Gastroenterol Hepatol 2012; 10: 925 ‐ 931.
dc.identifier.citedreferenceMpabanzi L, Jalan R. Neurological complications of acute liver failure: pathophysiological basis of current management and emerging therapies. Neurochem Int 2012; 60: 736 ‐ 742.
dc.identifier.citedreferenceEnns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea‐cycle disorders. N Engl J Med 2007; 356: 2282 ‐ 2292.
dc.identifier.citedreferenceAcharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of L‐ornithine L‐aspartate in acute liver failure: a double‐blind, randomized, placebo‐controlled study. Gastroenterology 2009; 136: 2159 ‐ 2168.
dc.identifier.citedreferenceJalan R, Lee WM. Treatment of hyperammonemia in liver failure: a tale of two enzymes. Gastroenterology 2009; 136: 2048 ‐ 2051.
dc.identifier.citedreferenceMokhtarani M, Diaz GA, Rhead W, Berry SA, Lichter‐Konecki U, Feigenbaum A, et al. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. Mol Genet Metab 2013; 110: 446 ‐ 453.
dc.identifier.citedreferenceJalan R, Wright G, Davies NA, Hodges SJ. L‐Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses 2007; 69: 1064 ‐ 1069.
dc.identifier.citedreferenceDavies NA, Wright G, Ytrebo LM, Stadlbauer V, Fuskevag OM, Zwingmann C, et al. L‐ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology 2009; 50: 155 ‐ 164.
dc.identifier.citedreferenceYtrebo LM, Kristiansen RG, Maehre H, Fuskevag OM, Kalstad T, Revhaug A, et al. L‐ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology 2009; 50: 165 ‐ 174.
dc.identifier.citedreferenceRama Rao KV, Norenberg MD. Glutamine in the pathogenesis of hepatic encephalopathy: the trojan horse hypothesis revisited. Neurochem Res 2014; 39: 593 ‐ 598.
dc.identifier.citedreferenceVentura‐Cots M, Arranz JA, Simon‐Talero M, Torrens M, Blanco A, Riudor E, et al. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open‐label, dose‐escalating, single‐cohort study. J Clin Gastroenterol 2013; 47: 881 ‐ 887.
dc.identifier.citedreferenceVentura‐Cots M, Concepcion M, Arranz JA, Simon‐Talero M, Torrens M, Blanco‐Grau A, et al. Impact of ornithine phenylacetate (OCR‐002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. Therap Adv Gastroenterol 2016; 9: 823 ‐ 835.
dc.identifier.citedreferenceKoch DG, Speiser JL, Durkalski V, Fontana RJ, Davern T, McGuire B, et al. The natural history of severe acute liver injury. Am J Gastroenterol 2017; 112: 1389 ‐ 1396.
dc.identifier.citedreferenceBernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 2007; 46: 1844 ‐ 1852.
dc.identifier.citedreferenceThibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 1994; 54: 1690 ‐ 1694.
dc.identifier.citedreferenceThibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 1995; 75: 2932 ‐ 2938.
dc.identifier.citedreferenceBernal W, Hyyrylainen A, Gera A, Audimoolam VK, McPhail MJ, Auzinger G, et al. Lessons from look‐back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 2013; 59: 74 ‐ 80.
dc.identifier.citedreferenceMurphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004; 39: 464 ‐ 470.
dc.identifier.citedreferenceMoldave K, Meister A. Enzymic acylation of glutamine by phenylacetic acid. Biochim Biophys Acta 1957; 24: 654 ‐ 655.
dc.identifier.citedreferenceMcGuire BM, Zupanets IA, Lowe ME, Xiao X, Syplyviy VA, Monteleone J, et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 2010; 51: 2077 ‐ 2085.
dc.identifier.citedreferenceZimmerman L, Jornvall H, Bergstrom J. Phenylacetylglutamine and hippuric acid in uremic and healthy subjects. Nephron 1990; 55: 265 ‐ 271.
dc.identifier.citedreferenceGhabril M, Zupanets IA, Vierling J, Mantry P, Rockey D, Wolf D, et al. Glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy: a pilot study of safety and effect on venous ammonia concentration. Clin Pharmacol Drug Dev 2013; 2: 278 ‐ 284.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep29621.pdf
Size:
453.3KB
Format:
PDF
View/Open
Name:
hep29621-sup-0001-suppinfo1.pdf
Size:
302.7KB
Format:
PDF
View/Open
Name:
hep29621_am.pdf
Size:
1.007MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.